VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung

R. T. Eagan, E. T. Creagan, J. N. Ingle, J. Rubin, S. Frytak, L. K. Kvols, T. R. Fleming

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

In an attempt to improve upon the 42% regression rate of the CAP-I regimen in patients with advanced adenocarcinoma of the lung, VP-16 was added to that regimen. VP-16, as a single agent, had a response rate of 12.5% (3/24) in a similar group of patients. The new regimen, V:CAP-I, had a tumor regression rate of 35% (7/20) and an estimated median survival of 171 days. Hence, the authors were unable to conclude that the addition of VP-16 to the CAP-I regimen statistically improved the regression rate of the CAP-I regimen.

Original languageEnglish (US)
Pages (from-to)105-109
Number of pages5
JournalUnknown Journal
Volume65
Issue number1
DOIs
StatePublished - 1979

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung'. Together they form a unique fingerprint.

  • Cite this

    Eagan, R. T., Creagan, E. T., Ingle, J. N., Rubin, J., Frytak, S., Kvols, L. K., & Fleming, T. R. (1979). VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung. Unknown Journal, 65(1), 105-109. https://doi.org/10.1177/030089167906500112